All News
Links:
Dr. John Cush RheumNow ( View Tweet)
AmericanJournalofHematology AjHematology ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Lymphoma in RA: Disease Activity Matters
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.
In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for lymphoma, with an odds ratio of 2.09 (95% CI 1.41-3.38), according to Gaetane Nocturne, MD, of Hôpital Bicêtre in Ile-de-France, and colleagues.
Links:
Dr. John Cush RheumNow ( View Tweet)
Not All Immunosuppression Alters Vaccine Immunogenicity
Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (B
Read ArticleTNF Inhibitor Induced IgA Vasculitis in IBD
A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after or during anti-TNF-α therapy.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs
The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an availabl
Read ArticleThe Predictive Value of Morning Stiffness
A prospective study evaluated the value and associations with morning stiffness in patients with clinically suspect arthralgia, and found that the presence of morning stiffness increases the odds of inflammation (as detected by CRP and MRI synovitis).
Read ArticleRheumatic Events With Checkpoint Inhibitors: Tumor Type Matters
Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Anakinra's Effects on COVID-19 Outcomes
Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote
Read ArticleCOVID Vaccine Booster Effective for Transplant Recipients in Small Trial
For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed.
Read ArticleRare Risk of Serious Adverse Events After COVID Vaccination
The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety signals
Read ArticleFDA Approves Anifrolumab in SLE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Read ArticleDMARD Effects on COVID-19 Outcomes
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug
Read ArticleRare Myocarditis Risk following COVID-19 Vaccine
MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination.
Read Article